Nov 14 (Reuters) - Commonwealth Bank of Australia (CBA) :
- QTRLY UNAUDITED STATUTORY NPAT A$ 2.5 BILLION VERSUS A$2.7 BILLION REPORTED LAST YEAR
- AUSTRALIAN ECONOMY REMAINS RESILIENT, SUPPORTED BY LOW UNEMPLOYMENT AND STRONG POPULATION GROWTH
- QTRLY UNAUDITED CASH NPAT A$2.5 BILLION VERSUS A$2.5 BILLION REPORTED LAST YEAR
- WE HAVE DELIVERED SOLID FINANCIAL OUTCOMES IN QUARTER
- AS AT SEPT-END, CET1 (LEVEL 2) RATIO OF 11.8%
- HIGHER INTEREST RATES ARE RESULTING IN SLOWING GROWTH AND CONSUMER SPENDING, WITH PRESSURE ON SOME HOUSEHOLDS AND BUSINESSES IN AUSTRALIA
- WE ARE VERY CONSCIOUS THAT MANY AUSTRALIANS ARE FEELING UNDER PRESSURE IN CURRENT ENVIRONMENT
- REMAIN OPTIMISTIC ON MEDIUM-TERM OUTLOOK FOR AUSTRALIA
- QTRLY LOAN IMPAIRMENT EXPENSE WAS A$198 MILLION
- WE HAVE SEEN A MODEST INCREASE IN CONSUMER ARREARS OVER RECENT MONTHS
- BALANCE SHEET STRENGTH COMBINED WITH OUR STRONG ORGANIC CAPITAL GENERATION ALLOWS US TO SUPPORT OUR CUSTOMERS THROUGH CHALLENGING TIMES
- HAS COMPLETED THE PURCHASE OF MORE THAN A$700 MILLION OF SHARES ON-MARKET TO NEUTRALISE THE IMPACT OF THE 2H23 DIVIDEND REINVESTMENT PLAN
- KEY CREDIT QUALITY INDICATORS REMAINED SOUND IN QUARTER WITH CONSUMER ARREARS REMAINING AT HISTORICALLY LOW LEVELS
- STRONG BANKS BENEFIT ALL AUSTRALIANS, AND WE REMAIN WELL POSITIONED TO CONTINUE TO SUPPORT OUR CUSTOMERS
- WE REMAIN WELL POSITIONED TO INVEST IN OUR COMMUNITIES AND PROVIDE STRENGTH AND STABILITY FOR BROADER AUSTRALIAN ECONOMY
- HAVE MADE GOOD PROGRESS ON OUR FY24 FUNDING REQUIREMENTS WITH A$17 BILLION RAISED TO DATE, REPRESENTING ABOUT 50% OF FY24 FUNDING TASK
- Forums
- ASX - By Stock
- CBA
- News: CBA CBA Posts Qtrly Unaudited Statutory NPAT Of A$2.5 Billion
CBA
commonwealth bank of australia.
Add to My Watchlist
1.19%
!
$188.44

News: CBA CBA Posts Qtrly Unaudited Statutory NPAT Of A$2.5 Billion
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$188.44 |
Change
-2.270(1.19%) |
Mkt cap ! $315.3B |
Open | High | Low | Value | Volume |
$190.50 | $191.06 | $188.13 | $150.0M | 801.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 35 | $188.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$188.48 | 55 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 213 | 188.520 |
7 | 317 | 188.510 |
3 | 144 | 188.500 |
4 | 143 | 188.490 |
4 | 86 | 188.480 |
Price($) | Vol. | No. |
---|---|---|
188.530 | 38 | 3 |
188.540 | 19 | 1 |
188.550 | 93 | 1 |
188.560 | 1 | 1 |
188.570 | 61 | 2 |
Last trade - 12.58pm 27/06/2025 (20 minute delay) ? |
Featured News
CBA (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online